The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $5 million grant to Congruence Therapeutics to advance the development of small molecules for Parkinson’s disease associated with mutations in the GBA1 gene. The research grant will support the optimization and clinical development of therapeutic candidates…
A five-year, $3.4 million grant from the National Institute of Environmental Health Sciences is supporting research into how manganese exposure may increase the risk of developing Parkinson’s disease. Manganese is an essential mineral the body needs in small amounts. However, high-level exposure, such as through certain pesticides, mining, or…
S.Biomedics said its stem cell-based therapy A9-DPC was found safe and effective in improving motor function over a one-year follow-up in people with Parkinson’s disease. The results apply to all 12 adults diagnosed with Parkinson’s for at least five years, who were treated with a single brain transplant…
Health Canada will review Knight Therapeutics’ application seeking approval of Crexont, an extended-release formulation of levodopa and carbidopa aimed at providing steady symptom control in Parkinson’s disease, the company said. The Parkinson’s therapy is designed to maintain consistent levels of levodopa and carbidopa in the body, prolonging…
A research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support a new study that’s investigating the biological mechanisms underlying anxiety as a symptom of Parkinson’s disease. Titled “Investigating the Mechanisms of Alpha-synuclein-induced Anxiety in a Novel Preclinical Model of Parkinson’s Disease,” the…
The U.S. Food and Drug Administration has approved Exablate Neuro, Insightec’s platform for noninvasive, MRI-guided focused ultrasound therapy, for the bilateral treatment of motor symptoms in patients with advanced Parkinson’s disease who no longer respond to medication. The therapy targets regions within the pallidothalamic tract, a brain pathway…
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s disease is complete, three months ahead of the original goal, the therapy’s developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up…
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein —…
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in…
VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to be safe and well tolerated after nearly one month of daily dosing in a clinical trial involving people with early-stage disease, according to the company. With these results, VTX3232 met…
Get regular updates to your inbox.
